Literature DB >> 11158021

Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women.

W S Browner1, L Y Lui, S R Cummings.   

Abstract

Osteoprotegerin (OPG) and its ligand are cytokines that regulate osteoclastogenesis and that may be involved in the regulation of vascular calcification. We examined whether serum OPG levels were associated with stroke, mortality, and cardiovascular risk factors, including diabetes, as well as with bone mineral density and fractures in a sample of 490 participants in a prospective cohort of white women, at least 65 yr of age. We found that OPG levels, assayed blinded from serum obtained at baseline, were about 30% greater in women with diabetes (mean +/- SD, 0.30 +/- 0.17 ng/mL) than in those without diabetes (0.23 +/- 0.10 ng/mL; P = 0.0001). OPG levels were associated with all-cause mortality [age-adjusted odds ratio, 1.4/SD (0.11 ng/mL) increase in serum OPG level; 95% confidence interval, 1.2--1.8] and cardiovascular mortality (odds ratio, 1.4; 95% confidence interval, 1.1--1.8); these effects were not confounded by diabetes. OPG levels were not associated with baseline bone mineral density or with subsequent strokes or fractures. The association of serum OPG levels with diabetes and with cardiovascular mortality raises the possibility that OPG may be a cause of or a marker for vascular calcification.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11158021     DOI: 10.1210/jcem.86.2.7192

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  121 in total

1.  Components of metabolic syndrome and risk of breast cancer by prognostic features in the study of osteoporotic fractures cohort.

Authors:  Katherine W Reeves; Vicki McLaughlin; Lisa Fredman; Kristine Ensrud; Jane A Cauley
Journal:  Cancer Causes Control       Date:  2012-06-02       Impact factor: 2.506

2.  Association of serum osteoprotegerin with left ventricular mass in African American adults with hypertension.

Authors:  Amit Noheria; Thomas H Mosley; Iftikhar J Kullo
Journal:  Am J Hypertens       Date:  2010-03-25       Impact factor: 2.689

Review 3.  Theories concerning the pathogenesis of the acute charcot foot suggest future therapy.

Authors:  William J Jeffcoate
Journal:  Curr Diab Rep       Date:  2005-12       Impact factor: 4.810

4.  Blood and interstitial flow in the hierarchical pore space architecture of bone tissue.

Authors:  Stephen C Cowin; Luis Cardoso
Journal:  J Biomech       Date:  2014-12-31       Impact factor: 2.712

Review 5.  Candidate-based proteomics in the search for biomarkers of cardiovascular disease.

Authors:  Leigh Anderson
Journal:  J Physiol       Date:  2004-12-20       Impact factor: 5.182

6.  Changes in the RANK ligand/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients.

Authors:  H Dobnig; L C Hofbauer; V Viereck; B Obermayer-Pietsch; A Fahrleitner-Pammer
Journal:  Osteoporos Int       Date:  2006-01-25       Impact factor: 4.507

7.  The contribution of serum osteoprotegerin to bone mass and vertebral fractures in postmenopausal women.

Authors:  Pedro Mezquita-Raya; Magdalena de la Higuera; Diego Fernández García; Guillermo Alonso; María Estrella Ruiz-Requena; Juan de Dios Luna; Fernando Escobar-Jiménez; Manuel Muñoz-Torres
Journal:  Osteoporos Int       Date:  2005-02-12       Impact factor: 4.507

8.  Bone morphogenetic proteins regulate osteoprotegerin and its ligands in human vascular smooth muscle cells.

Authors:  Kirsten Q T Nguyen; Ping Olesen; Thomas Ledet; Lars Melholt Rasmussen
Journal:  Endocrine       Date:  2007-09-29       Impact factor: 3.633

9.  Heparan Sulfate Regulates the Structure and Function of Osteoprotegerin in Osteoclastogenesis.

Authors:  Miaomiao Li; Shuying Yang; Ding Xu
Journal:  J Biol Chem       Date:  2016-10-03       Impact factor: 5.157

Review 10.  Vascular calcification and osteolysis in diabetic neuropathy-is RANK-L the missing link?

Authors:  W Jeffcoate
Journal:  Diabetologia       Date:  2004-08-21       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.